IFW

TRANSMITTAL LETTER (General - Patent Pending)	Docket No. 01419/2/US

In Re Application Of: **Lu et al.**

OIPE JC61 JUN 07 2004 PATENT & TRADEMARK OFFICE

Serial No.	Filing Date	Examiner	Group Art Unit
10/683,943	**October 10, 2003**	**Unknown**	**1615**

Title: **DERMAL DELIVERY OF A WATER-SOLUBLE SELECTIVE CYCLOOXYGENASE-2 INHIBITOR**

TO THE COMMISSIONER FOR PATENTS:

Transmitted herewith is:

Information Disclosure Statement; Form 1449; Cited References (10); Itemized Postcard.

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **19-1025** as described below.
  - ☐ Charge the amount of
  - ☒ Credit any overpayment.
  - ☒ Charge any additional fee required.

Patricia K Fitzsimmons

Signature

Dated: **June 3, 2004**

Patricia K. Fitzsimmons, Reg. No. 52,894
Pharmacia Corporation of Pfizer Inc.
P.O. Box 1027
Chesterfield, Missouri 63006
314.274.1490

I certify that this document and fee is being deposited on **June 3, 2004** with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Linda K. Cooper

Signature of Person Mailing Correspondence

Linda K. Cooper

Typed or Printed Name of Person Mailing Correspondence

cc:

OIPE JC61
JUN 07 2004
PATENT & TRADEMARK OFFICE

PATENT
Case 01419/2/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	Guang Wei Lu et al.	GROUP ART UNIT:	1615
SERIAL NO.:	10/683,943	CONFIRMATION NO.:	2772
EXAMINER:	Unknown	ATTORNEY DOCKET NO.:	01419/2/US
FILED:	October 10, 2003		

TITLE: DERMAL DELIVERY OF A WATER-SOLUBLE SELECTIVE CYCLOOXYGENASE-2 INHIBITOR

June 3, 2004

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97 and 1.98

Commissioner of Patents
Box 1450
Alexandria, VA 22313

Sir:

This Information Disclosure Statement is filed pursuant to 37 CFR 1.97 and 1.98 and MPEP §609. Copies of the references listed on the attached Form PTO-1449 are enclosed herein.

Each item contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. No fee is required under §1.97.

Please charge any fee required by §1.97 to Deposit Account No. 19-1025.

Respectfully submitted,

Patricia K. Fitzsimmons
Attorney for Applicants
Registration No. 52,894
(314) 274-1490

Pharmacia Corporation
of Pfizer Inc.
Global Patent Department
Post Office Box 1027
St. Louis, MO 63006

OIPE JC81 JUN 07 2004 PATENT & TRADEMARK OFFICE

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 01419/2/US	APPLICATION NO.: 10/683,943
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	INVENTOR: Guang Wei Lu et al.	
(Use several sheets if necessary)	Filed: 10/10/2003	Group: 1615

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
		5 9 3 2 5 9 8	08/03/1999	Talley et al.	514/341		01/12/1998
		6 3 0 9 6 6 3	10/30/2001	Patel et al.	424/450		08/17/1999

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
	A2	WO 02 0 7 8 6 2 5	10/10/2002	PCT	A61K		X	
	A1	WO 98 1 8 4 1 6	05/07/1998	PCT	A61F	13/02	X	
	A1	WO 00 5 1 5 7 5	09/08/2000	PCT	A61K	9/70	X	
	A2	WO 01 5 2 8 9 7	07/26/2001	PCT	A61K	47/12	X	
	A1	WO 02 0 2 1 1 1	01/10/2002	PCT	A61K	31/415		X
	A2	WO 02 0 9 6 4 3 5	12/05/2002	PCT	A61K	31/635	X	
	A1	WO 20 04 0 1 2 7 3 4	02/12/2004	PCT	A61K	31/42		X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
		International Search Report; International Application No. PCT/US03/35638; International filing date 07/11/2003 (day, month, year); 9 pgs.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	